Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium [177Lu]-FAP-75 in Advanced Solid Tumors
NCT06553846Phase 1Not yet recruiting
- Sponsor
- Fudan University
- Start
- Aug 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 177Lu-FAPI-FUSCC in solid tumor, sponsored by Fudan University. Primary endpoint: Overall Response Rate at 12 months. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
177Lu-FAPI-FUSCC
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06553846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06553846.